Pharmaceutical rebate debated in Germany

05/1/2013 | Financial Times (tiered subscription model)

The expiration of Germany's 16% rebate for pharmaceuticals at the end of 2013 is prompting debate about its necessity. The country's Statutory Health Insurance funds, which benefit from the rebate, made a huge surplus last year, according to price consultant Andreas Guhl. Contracts will expire Dec. 31, so a decision will likely be made about August to October. "I can't see the likelihood of the rebate disappearing completely," Guhl said.

View Full Article in:

Financial Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD